Page last updated: 2024-10-24

carvedilol and Cardiotoxicity

carvedilol has been researched along with Cardiotoxicity in 27 studies

Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.

Research Excerpts

ExcerptRelevanceReference
"Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an early decrease in LVEF."9.41Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. ( Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ, 2021)
"We designed a pilot, randomized controlled, two-arm clinical trial with 32 patients to evaluate the effects of non-hypoxic cardiac preconditioning (DHA) plus carvedilol on subclinical cardiotoxicity in breast cancer patients undergoing anthracycline treatment."9.34Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled tria ( Aguayo, R; Carrasco, R; Cortés, I; Erazo, M; Gormaz, JG; Hasson, D; Henriquez, P; Morales, M; Nes, K; Ramirez, MC; Ramos, C; Salas, C; Schuster, A; Sotomayor, CG, 2020)
"This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity."9.27Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. ( Abduch, MC; Avila, MS; Ayub-Ferreira, SM; Bittencourt Viana Cruz, CB; Bittencourt, MS; Bocchi, EA; das Dores Cruz, F; de Barros Wanderley, MR; de Paula Costa, RL; Ferrari, MSM; Gonçalves Brandão, SM; Guimaraes, GV; Hajjar, LA; Higuchi-Dos-Santos, MH; Hoff, PM; Issa, VS; Kalil Filho, R; Lofrano Alves, MS; Mano, MS; Rigaud, VOC; Sahade, M, 2018)
"We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy."9.24Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. ( Fink, A; Guglin, M; Krischer, J; Munster, P, 2017)
"In this randomized, single-blind, placebo-controlled study, 91 women with recently diagnosed breast cancer undergoing ANT therapy were randomly assigned to groups treated with either carvedilol (n = 46) or placebo (n = 45)."9.24Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. ( Baghyari, S; Esmaili, K; Janbabai, G; Nabati, M; Yazdani, J, 2017)
"In this trial, 70 female patients with breast cancer who were candidates to receive doxorubicin were enrolled, from which 30 were selected randomly to receive carvedilol 6."9.22Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial. ( Fazlinezhad, A; Homaei Shandiz, F; Hosseini, G; Mostafavi Toroghi, H; Tashakori Beheshti, A; Zarifian, A, 2016)
" Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy."7.96In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020)
"Cadmium (Cd) is a highly toxic heavy metal with several harmful effects including cardiotoxicity."7.91Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway. ( Bayoumi, AMA; El-Hussieny, M; Refaie, MMM; Shehata, S, 2019)
"In this study, we tried to demonstrate the effects of adding human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) to carvedilol in improving the doxorubicin- induced cardiotoxicity in rats."7.88Umbilical cord blood-mesenchymal stem cells and carvedilol reduce doxorubicin- induced cardiotoxicity: Possible role of insulin-like growth factor-1. ( Abbas, NAT; Abdel Aal, SM; Mousa, HSE, 2018)
" Patients at high risk of cardiotoxicity (cardiac troponin I concentrations in the upper tertile during chemotherapy) were randomized to standard care plus cardioprotection (combination carvedilol and candesartan therapy) or standard care alone."5.69Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. ( Borley, A; Broom, A; Collins, G; Eddie, L; Everett, RJ; Fletcher, A; Guppy, A; Hall, P; Henriksen, PA; Japp, A; Joshi, SS; Lang, NN; Lewis, S; Lord, S; Maclean, M; MacPherson, IR; McKay, P; McVicars, H; Mills, NL; Newby, DE; Oikonomidou, O; Payne, JR; Primrose, L; Radford, J; Rodriguez, A; Rowntree, C; Singh, T; Stavert, H; Williams, MC, 2023)
"Carvedilol (CAR) is a β-blocker used to treat high blood pressure and heart failure."5.51Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. ( Yang, JJ; Zhang, HS; Zhang, QL, 2019)
"Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an early decrease in LVEF."5.41Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. ( Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ, 2021)
"We designed a pilot, randomized controlled, two-arm clinical trial with 32 patients to evaluate the effects of non-hypoxic cardiac preconditioning (DHA) plus carvedilol on subclinical cardiotoxicity in breast cancer patients undergoing anthracycline treatment."5.34Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled tria ( Aguayo, R; Carrasco, R; Cortés, I; Erazo, M; Gormaz, JG; Hasson, D; Henriquez, P; Morales, M; Nes, K; Ramirez, MC; Ramos, C; Salas, C; Schuster, A; Sotomayor, CG, 2020)
"This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity."5.27Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. ( Abduch, MC; Avila, MS; Ayub-Ferreira, SM; Bittencourt Viana Cruz, CB; Bittencourt, MS; Bocchi, EA; das Dores Cruz, F; de Barros Wanderley, MR; de Paula Costa, RL; Ferrari, MSM; Gonçalves Brandão, SM; Guimaraes, GV; Hajjar, LA; Higuchi-Dos-Santos, MH; Hoff, PM; Issa, VS; Kalil Filho, R; Lofrano Alves, MS; Mano, MS; Rigaud, VOC; Sahade, M, 2018)
"We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy."5.24Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. ( Fink, A; Guglin, M; Krischer, J; Munster, P, 2017)
"In this randomized, single-blind, placebo-controlled study, 91 women with recently diagnosed breast cancer undergoing ANT therapy were randomly assigned to groups treated with either carvedilol (n = 46) or placebo (n = 45)."5.24Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. ( Baghyari, S; Esmaili, K; Janbabai, G; Nabati, M; Yazdani, J, 2017)
"Cardiac CARE will examine whether cardiac biomarker monitoring identifies patients at risk of left ventricular dysfunction following anthracycline chemotherapy and whether troponin-guided treatment with combination candesartan and carvedilol therapy prevents the development of left ventricular dysfunction in these high-risk patients."5.22Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. ( Borley, A; Broom, A; Collins, G; Guppy, A; Hall, P; Henriksen, PA; Lang, NN; Lewis, S; Lord, S; Maclean, M; MacPherson, IR; McKay, P; McVicars, H; Mills, NL; Newby, DE; Oikonomidou, O; Payne, JR; Radford, J; Rowntree, C; Scott, F, 2022)
"In this trial, 70 female patients with breast cancer who were candidates to receive doxorubicin were enrolled, from which 30 were selected randomly to receive carvedilol 6."5.22Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial. ( Fazlinezhad, A; Homaei Shandiz, F; Hosseini, G; Mostafavi Toroghi, H; Tashakori Beheshti, A; Zarifian, A, 2016)
" Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy."3.96In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020)
"Cadmium (Cd) is a highly toxic heavy metal with several harmful effects including cardiotoxicity."3.91Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway. ( Bayoumi, AMA; El-Hussieny, M; Refaie, MMM; Shehata, S, 2019)
"In this study, we tried to demonstrate the effects of adding human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) to carvedilol in improving the doxorubicin- induced cardiotoxicity in rats."3.88Umbilical cord blood-mesenchymal stem cells and carvedilol reduce doxorubicin- induced cardiotoxicity: Possible role of insulin-like growth factor-1. ( Abbas, NAT; Abdel Aal, SM; Mousa, HSE, 2018)
" To tackle this issue, we established embryonic zebrafish models of doxorubicin-, adrenaline- and terfenadine-induced cardiotoxicity with unified dosing regimen which eventually enabled head-to-head comparison of the drugs."1.72Pharmacological assessment of zebrafish-based cardiotoxicity models. ( Maciag, M; Mierzejewska, M; Plazinska, A; Wnorowski, A, 2022)
"Carvedilol (CAR) is a β-blocker used to treat high blood pressure and heart failure."1.51Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. ( Yang, JJ; Zhang, HS; Zhang, QL, 2019)
"Cardiotoxicity is associated with the chronic use of doxorubicin leading to cardiomyopathy and heart failure."1.46Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. ( Alves, MS; Ávila, MS; Ayub-Ferreira, SM; Bocchi, EA; Brandão, SM; Cruz, CB; Cruz, FD; Cunha-Neto, E; Ferreira, LR; Guimarães, GV; Issa, VS; Rigaud, VO; Santos, MH, 2017)

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's18 (66.67)24.3611
2020's9 (33.33)2.80

Authors

AuthorsStudies
Maciag, M1
Wnorowski, A1
Mierzejewska, M1
Plazinska, A1
Henriksen, PA2
Hall, P2
Oikonomidou, O2
MacPherson, IR2
Maclean, M2
Lewis, S2
McVicars, H2
Broom, A2
Scott, F1
McKay, P2
Borley, A2
Rowntree, C2
Lord, S2
Collins, G2
Radford, J2
Guppy, A2
Payne, JR2
Newby, DE2
Mills, NL2
Lang, NN2
Mohamed, RMSM1
Ahmad, EA1
Omran, BHF1
Sakr, AT1
Ibrahim, IAAE1
Mahmoud, MF1
El-Naggar, ME1
Joshi, SS1
Singh, T1
Rodriguez, A1
Fletcher, A1
Everett, RJ1
Stavert, H1
Eddie, L1
Primrose, L1
Williams, MC1
Japp, A1
Sun, J1
Shang, H1
Yang, X1
Xing, Y1
Ozkalayci, F1
Tanboga, IH1
Carrasco, R1
Ramirez, MC1
Nes, K1
Schuster, A1
Aguayo, R1
Morales, M1
Ramos, C1
Hasson, D1
Sotomayor, CG1
Henriquez, P1
Cortés, I1
Erazo, M1
Salas, C1
Gormaz, JG1
Beiranvand, E1
Ostad, SN1
Ardakani, EM1
Torkashvand, F1
Sardari, S1
Vaziri, B1
Alanazi, A1
Fadda, L1
Alhusaini, A1
Ahmad, R1
Lee, M1
Chung, WB1
Lee, JE1
Park, CS1
Park, WC1
Song, BJ1
Youn, HJ1
Guglin, M1
Munster, P1
Fink, A1
Krischer, J1
Avila, MS3
Ayub-Ferreira, SM2
de Barros Wanderley, MR1
das Dores Cruz, F1
Gonçalves Brandão, SM1
Rigaud, VOC1
Higuchi-Dos-Santos, MH1
Hajjar, LA1
Kalil Filho, R1
Hoff, PM1
Sahade, M1
Ferrari, MSM1
de Paula Costa, RL1
Mano, MS1
Bittencourt Viana Cruz, CB1
Abduch, MC1
Lofrano Alves, MS1
Guimaraes, GV2
Issa, VS2
Bittencourt, MS1
Bocchi, EA3
Mousa, HSE1
Abdel Aal, SM1
Abbas, NAT1
Galderisi, M1
Sorrentino, R1
Esposito, R1
Ayub Ferreira, SM1
Kheiri, B1
Abdalla, A1
Osman, M1
Haykal, T1
Chahine, A1
Ahmed, S1
Osman, K1
Hassan, M1
Bachuwa, G1
Bhatt, DL1
Zhang, QL1
Yang, JJ1
Zhang, HS1
Huang, S1
Zhao, Q1
Yang, ZG1
Diao, KY1
He, Y1
Shi, K1
Shen, MT1
Fu, H1
Guo, YK1
Zhan, T1
Daniyal, M1
Li, J1
Mao, Y1
Barbosa, RR1
Bourguignon, TB1
Torres, LD1
Arruda, LS1
Jacques, TM1
Serpa, RG1
Calil, OA1
Barbosa, LFM1
Refaie, MMM1
El-Hussieny, M1
Bayoumi, AMA1
Shehata, S1
Barac, A1
Blaes, A1
Lynce, F1
Tashakori Beheshti, A1
Mostafavi Toroghi, H1
Hosseini, G1
Zarifian, A1
Homaei Shandiz, F1
Fazlinezhad, A1
El-Shitany, NA1
El-Desoky, K1
Armenian, SH1
Hudson, MM1
Chen, MH1
Colan, SD1
Lindenfeld, L1
Mills, G1
Siyahian, A1
Gelehrter, S1
Dang, H1
Hein, W1
Green, DM1
Robison, LL1
Wong, FL1
Douglas, PS1
Bhatia, S1
Rigaud, VO1
Ferreira, LR1
Brandão, SM1
Cruz, FD1
Santos, MH1
Cruz, CB1
Alves, MS1
Cunha-Neto, E1
Nabati, M1
Janbabai, G1
Baghyari, S1
Esmaili, K1
Yazdani, J1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)[NCT06005259]Phase 4264 participants (Anticipated)Interventional2023-10-01Not yet recruiting
Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity. A Randomized Double Blind Study.[NCT01724450]Phase 3200 participants (Actual)Interventional2013-04-30Completed
Can Bisoprolol Administration Prevent Anthracycline-induced Cardiotoxicity?: a Double-blind Randomized Trial.[NCT05175066]Phase 380 participants (Actual)Interventional2020-11-12Completed
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial[NCT02717507]Phase 2196 participants (Actual)Interventional2016-04-04Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Proportion of Participants With Average Adherence > 90%

The number of pills taken out of the total prescribed in a 3-month period, averaged across all study time points. The proportion of participants with average adherence rate >90% is computed by arm and corresponding 95% confidence intervals are reported. (NCT02717507)
Timeframe: Average adherence across 6 months, 12 months, 18 months, 24 months after treatment initiation are calculated.

Interventionproportion of participants (Number)
Arm I (Carvedilol)0.483
Arm II (Placebo)0.517

Proportion of Patients With Reportable Adverse Events as Described in the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).

Patients with toxicities reported via CTEP-AERS and all Grade ≥ 2 adverse events (AEs) that can be attributed probably or definitely to the study drug are considered to have AEs. The proportion of patients with AEs are reported by arm with corresponding 95% confidence intervals. (NCT02717507)
Timeframe: From baseline to month 24 since baseline

InterventionProportion of patients with AE (Number)
Arm I (Carvedilol)0.0267
Arm II (Placebo)0

"Proportion of Patients Who Responded Moderately, Quite a Bit, or Extremely to How Bothersome the Symptom of DIARRHEA Was at Any Post-day 0 Assessment Time Point."

"In a questionnaire, patients responded Yes/No to certain symptoms. If answered Yes, they selected slightly, moderately, quite a bit, or extremely regarding how bothersome the symptom was. The proportion of participants responding with any of these three categories was calculated by arm, and corresponding 95% confidence intervals are reported." (NCT02717507)
Timeframe: responses at days 14 to 730 were combined

,
InterventionProportion of patients (Number)
DiarrheaSkin rashItchy skinDry MouthEasy bruisingNosebleedsSunburn easilyWeight gainFluid retentionSwollen feetIncreased sweatingFeeling weak in parts of your bodyShortness of breath or wheezingChest pain or heavinessHeart racing or skipping beatsFeeling shaky or having tremorsDecreased bodily movementFeeling nervousFeeling downhearted, sad, and/or tearfulMood swingsDizziness and/or lightheadednessDizziness upon standing (from sitting or lying down)InsomniaDifficulty concentratingInterrupted sleepTendency to take napsTiredwheezingFeeling unusually tiredFalling asleep at inappropriate timesRinging in the earsDifficulty breathingSensation that I have to urinate much of the timeDiscoloration of urine (ie, bloody)Decreased libidoUnusually heavy menstrual flows (N/A if postmenopausal or male)
Arm I (Carvedilol)0.05330.09330.14670.06670.01330.06670.09330.05330.026700.09330.09330.09330.080.080.05330.01330.14670.20.120.160.14670.17330.10670.20.120.22670.02670.05330.02670.066700.06670.2
Arm II (Placebo)0.13160.07890.14470.17110.09210.05260.05260.07890.03950.09210.07890.13160.03950.09210.03950.07890.03950.17110.11840.09210.13160.15790.17110.13160.21050.10530.22370.03950.092100.07890.03950.05260.111

Average Alanine Aminotransferase

A liver function measurement (in U/L). Normal range is 8-48 IU/L. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
InterventionIU/L (Mean)
BL6m12m18m24m
Arm I (Carvedilol)29.12228.01430.14827.19629.86
Arm II (Placebo)30.46732.15831.15530.53629.245

Average Aspartate Aminotransferase

A liver function measurement (in U/L). Normal range is 14-20 for men, 10-36 for women. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
InterventionIU/L (Mean)
BL6m12m18m24m
Arm I (Carvedilol)26.60824.06825.42624.37524.561
Arm II (Placebo)25.77326.34227.01428.41127.038

Average Bilirubin

A liver function measurement (in mg/dL). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionmg/dL (Mean)
BL6m12m18m24m
Arm I (Carvedilol)0.56340.59730.5630.5930.5561
Arm II (Placebo)0.49890.49420.49690.5070.5449

Average Cardiac N-terminal Pro B-type Natriuretic Peptide

N-terminal pro b-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionpg/mL (Mean)
BL6m12m18m24m
Arm I (Carvedilol)85.630190.753687.716799.4912101.8333
Arm II (Placebo)115.7222128.9565115.636493.2105107.849

Average Cardiac Troponin I

Troponin I is a biomarker for myocardial cell injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionng/mL (Mean)
BL6m12m18m24m
Arm I (Carvedilol)0.004460.002650.004670.007370.01111
Arm II (Placebo)0.00110.001740.007420.006840.01132

Average Ejection Fraction

The percentage of blood leaving the heart at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
InterventionPercent (Mean)
BL6m12m18m24
Arm I (Carvedilol)57.658.1658.0757.3558.16
Arm II (Placebo)57.4256.8456.6157.657.5

Average Fractional Shortening

A measure to assess preload and afterload (in %). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionpercent (Mean)
BL6m12m18m24
Arm I (Carvedilol)28.536228.540929.612127.821928.0302
Arm II (Placebo)28.433927.686628.108527.889128.5953

Average Galectin-3

A protein produced by activated macrophages, and a member of a family of β-galactoside-binding lectings and promotes cardiac fibroblast proliferation and collagen synthesis following myocadial injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionng/mL (Mean)
BL6m12m18m24m
Arm I (Carvedilol)4.44644.32523.73453.45483.8073
Arm II (Placebo)5.25384.37354.34154.02144.0791

Average Left Ventricular End-diastolic Dimension

The amount of blood (in ml) in the heart's left ventricle just before the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionml (Mean)
BL6m12m18m24m
Arm I (Carvedilol)99.750799.3216102.378101.174100.659
Arm II (Placebo)93.315595.743496.500299.465698.9602

Average Left Ventricular End-diastolic Dimension

Thickness of cardiac muscle (in ml) of the left ventricle at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionml (Mean)
BL6m12m18m24
Arm I (Carvedilol)4.58364.60354.6364.60324.5147
Arm II (Placebo)4.52694.5650.05564.54624.5976

Average Left Ventricular End-systolic Volume

The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventioncentimeter (Mean)
BL6m12m18m24m
Arm I (Carvedilol)03.27653.29013.2623.323.2441
Arm II (Placebo)3.23963.30233.29643.27983.286

Average Left Ventricular End-systolic Volume

The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionml (Mean)
BL6m12m18m24m
Arm I (Carvedilol)42.219341.612842.843743.145342.0086
Arm II (Placebo)39.735441.383941.81131.60542.442

Average Left Ventricular End-systolic Wall Stress

Echocardiographic measure of left ventricular (LV) afterload based on LV pressure (P), volume (V), and wall thickness (T), calculated by the formula (P x V)/T, which equals the number referred to below in the Measure Type. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventiong/cm^2 (Mean)
BL6m12m18m24m
Arm I (Carvedilol)93.289290.308888.98493.926789.2513
Arm II (Placebo)90.613596.835696.061691.645894.0647

Average Left Ventricular Mass

The weight of the left ventricle adjusted for body surface area (in g/m2). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventiong/m2 (Mean)
BL6m12m18m24m
Arm I (Carvedilol)57.486258.283960.211657.705358.3315
Arm II (Placebo)57.932257.092459.450859.179359.1026

Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz)

Z-score of the ratio of left ventricular (LV) posterior wall dimension of systole to internal LV dimension in diastole, calculated for each subject by subtracting the reference healthy population mean, then dividing by the standard deviation. The Z-score indicates the number of standard deviations away from the mean of the reference population. Negative Z- score indicates worse outcome. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionz-score (Mean)
BL6m12m18m24m
Arm I (Carvedilol)-0.1372-0.2167-0.2416-0.23750.0213
Arm II (Placebo)-0.08930.3215-0.2367-0.19740.1834

Average N-terminal Pro B-type Natriuretic Peptide

B-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionpg/mL (Mean)
BL6m12m18m24m
Arm I (Carvedilol)27.383631.840626.820335.80734.625
Arm II (Placebo)31.432434.185733.294132.280733.3774

Average Peak Early Atrial Divided by Peak Late Atrial Velocities

"Ratio of peak velocity blood flow from left ventricular relaxation in early diastole (E wave) to peak velocity flow in late diastole caused by atrial contraction (A wave). Number shown for Unit of Measure refers to this ratio. Normal: >1. Impaired: <1. The mean is reported by arm at each timepoint with corresponding standard errors." (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation

,
Interventionratio (Mean)
BL6m12m18m24m
Arm I (Carvedilol)1.7281.6421.7231.7321.603
Arm II (Placebo)1.7320.0711.7221.7321.64

Reviews

5 reviews available for carvedilol and Cardiotoxicity

ArticleYear
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
    Circulation. Heart failure, 2022, Volume: 15, Issue:7

    Topics: Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Antibiotics, Antineoplastic; Breast Neopl

2022
Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
    The American journal of cardiology, 2018, 12-01, Volume: 122, Issue:11

    Topics: Anthracyclines; Antioxidants; Cardiotoxicity; Carvedilol; Heart Diseases; Humans; Neoplasms

2018
Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol.
    Heart failure reviews, 2019, Volume: 24, Issue:3

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Antineoplastic Agents; Cardiotoxicity; Carvedilol; Echocar

2019
Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials.
    Herz, 2020, Volume: 45, Issue:Suppl 1

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Calcium Channel Blockers; Cardiotoxicity; Carvedilol; H

2020
Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.
    Revista da Associacao Medica Brasileira (1992), 2018, Volume: 64, Issue:8

    Topics: Adrenergic beta-Antagonists; Adult; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Carvedilol;

2018

Trials

8 trials available for carvedilol and Cardiotoxicity

ArticleYear
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
    Circulation, 2023, Nov-21, Volume: 148, Issue:21

    Topics: Adrenergic beta-Antagonists; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardioto

2023
Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled tria
    Trials, 2020, Feb-04, Volume: 21, Issue:1

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antibiotics, Antineoplastic; Antioxidants; Bio

2020
Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
    Cancer medicine, 2021, Volume: 10, Issue:12

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antibiotics, Antineoplastic; Antihype

2021
Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
    American heart journal, 2017, Volume: 188

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antineopla

2017
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
    Journal of the American College of Cardiology, 2018, 05-22, Volume: 71, Issue:20

    Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi

2018
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
    Journal of the American College of Cardiology, 2018, 05-22, Volume: 71, Issue:20

    Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi

2018
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
    Journal of the American College of Cardiology, 2018, 05-22, Volume: 71, Issue:20

    Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi

2018
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
    Journal of the American College of Cardiology, 2018, 05-22, Volume: 71, Issue:20

    Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi

2018
Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial.
    Cardiology, 2016, Volume: 134, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Carbazoles; Cardi

2016
Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk
    BMC cardiovascular disorders, 2016, 10-04, Volume: 16, Issue:1

    Topics: Adrenergic beta-Antagonists; Age Factors; Anthracyclines; Antibiotics, Antineoplastic; Carbazoles; C

2016
Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Journal of cardiovascular pharmacology, 2017, Volume: 69, Issue:5

    Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Atrial Function, Left; Biomarkers; Breast

2017

Other Studies

14 other studies available for carvedilol and Cardiotoxicity

ArticleYear
Pharmacological assessment of zebrafish-based cardiotoxicity models.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 148

    Topics: Animals; Cardiomyopathies; Cardiotoxicity; Carvedilol; Doxorubicin; Zebrafish

2022
Carvedilol ameliorates dexamethasone-induced myocardial injury in rats independent of its action on the α1-adrenergic receptor.
    Naunyn-Schmiedeberg's archives of pharmacology, 2022, Volume: 395, Issue:12

    Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiotoxicity; Carvedilol; Dexamethasone; Phenyle

2022
Effect of Cardioprotective Drugs on Chemotherapy-Induced Heart Failure and New Risk Stratification.
    Journal of the American College of Cardiology, 2019, 10-01, Volume: 74, Issue:13

    Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedilol; Heart Failure; Humans; Lisinopr

2019
Strategies to Prevent Cardiotoxicity.
    Journal of the American College of Cardiology, 2019, 10-01, Volume: 74, Issue:13

    Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedilol; Humans; Lisinopril; Neoplasms;

2019
In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity.
    Drug research, 2020, Volume: 70, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Breast Neoplasms; Cardiotoxicity; Carved

2020
Antioxidant, antiapoptotic, and antifibrotic effects of the combination of liposomal resveratrol and carvedilol against doxorubicin-induced cardiomyopathy in rats.
    Journal of biochemical and molecular toxicology, 2020, Volume: 34, Issue:7

    Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Cardiomyopathies; Cardiotoxicity; Car

2020
Umbilical cord blood-mesenchymal stem cells and carvedilol reduce doxorubicin- induced cardiotoxicity: Possible role of insulin-like growth factor-1.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 105

    Topics: Animals; Carbazoles; Cardiotoxicity; Carvedilol; Doxorubicin; Fetal Blood; Humans; Insulin-Like Grow

2018
Can Carvedilol Prevent Chemotherapy-Related Cardiotoxicity?: A Dream to Be Balanced With Tolerability.
    Journal of the American College of Cardiology, 2018, 09-04, Volume: 72, Issue:10

    Topics: Cardiotoxicity; Carvedilol; Doxorubicin; Humans; Stroke Volume

2018
Reply: Can Carvedilol Prevent Chemotherapy-Related Cardiotoxicity?: A Dream to Be Balanced With Tolerability.
    Journal of the American College of Cardiology, 2018, 09-04, Volume: 72, Issue:10

    Topics: Cardiotoxicity; Carvedilol; Doxorubicin; Humans; Stroke Volume

2018
Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 109

    Topics: Abietanes; Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Autophagy; Cardiotoxicity;

2019
Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway.
    Environmental toxicology and pharmacology, 2019, Volume: 70

    Topics: Animals; Cadmium; Cardiotonic Agents; Cardiotoxicity; Carvedilol; Heme Oxygenase (Decyclizing); Male

2019
Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy: End of One Size Fits All.
    Journal of the American College of Cardiology, 2019, 06-11, Volume: 73, Issue:22

    Topics: Breast Neoplasms; Cardiotoxicity; Carvedilol; Humans; Lisinopril; Trastuzumab

2019
Protective Effects of Carvedilol and Vitamin C against Azithromycin-Induced Cardiotoxicity in Rats via Decreasing ROS, IL1-β, and TNF-α Production and Inhibiting NF-κB and Caspase-3 Expression.
    Oxidative medicine and cellular longevity, 2016, Volume: 2016

    Topics: Animals; Anti-Bacterial Agents; Ascorbic Acid; Azithromycin; Carbazoles; Cardiotoxicity; Carvedilol;

2016
Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Oncotarget, 2017, Jan-24, Volume: 8, Issue:4

    Topics: Biomarkers; Breast Neoplasms; Carbazoles; Cardiotoxicity; Carvedilol; Doxorubicin; Female; Humans; M

2017